Thiogenesis Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 1
1 (25.0%)A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Thiogenesis Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06990984
A Study to Assess TTI-0102 vs Placebo in MELAS Patients
Phase 2
Recruiting
- Conditions
- MELAS SyndromeMitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Thiogenesis Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06644534
- Locations
- 🇫🇷
Angers University Hospital Center (CHU Angers), Angers, France
🇳🇱Radboud University Medical Center, Nijmegen, Netherlands
Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
Phase 2
Withdrawn
- Conditions
- COVID-19 Acute Respiratory Distress SyndromeCOVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Thiogenesis Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05212662
News
No news found